Kuangli Bio-Tech Holdings Co., Ltd. reported earnings results for the third quarter and nine months ended September 30, 2022. For the third quarter, the company reported sales was TWD 112.46 million compared to TWD 128.71 million a year ago. Net loss was TWD 5.03 million compared to TWD 7.13 million a year ago. Basic loss per share from continuing operations was TWD 0.09 compared to TWD 0.1 a year ago. Diluted loss per share from continuing operations was TWD 0.09 compared to TWD 0.1 a year ago. Basic loss per share was TWD 0.09 compared to TWD 0.14 a year ago. Diluted loss per share was TWD 0.09 compared to TWD 0.14 a year ago.
For the nine months, sales was TWD 234.57 million compared to TWD 181.49 million a year ago. Net loss was TWD 58.96 million compared to net income of TWD 28.66 million a year ago. Basic loss per share was TWD 1.05 compared to basic earnings per share of TWD 0.57 a year ago. Diluted loss per share was TWD 1.05 compared to diluted earnings per share of TWD 0.57 a year ago.